Browsing by Author "Albanell Mestres, Joan"

Sort by: Order: Results:

  • A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse
    Prat, Aleix; Alba, Emilio; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified.Experimental Design: Research-based ...
  • A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition
    Vincent, Theresa; Neve, Etienne P.A.; Johnson, Jill R.; Kukalev, Alexander; Rojo, Federico; Albanell Mestres, Joan; Pietras, Kristian; Virtanen, Ismo; Philipson, Lennart; Leopold, Philip L.; Crystal, Ronald G.; García de Herreros, Antonio; Moustakas, Aristidis; Petterson, Ralf F.; Fuxe, Jonas (Nature Research, 2009)
    Epithelial-mesenchymal transition (EMT) is essential for organogenesis and is triggered during carcinoma progression to an invasive state. Transforming growth factor-beta (TGF-beta) cooperates with signalling pathways, ...
  • Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
    Van Emburgh, Beth O.; Vidal Barrull, Joana; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Montagut Viladot, Clara; Bardelli, Alberto (Nature Publishing Group, 2016)
    Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of ...
  • Acquired resistance to the anti-EFGR monoclonal antibody cetuximab in colorectal cancer
    Dalmases Massegú, Alba (Universitat Pompeu Fabra, 2012-10-03)
    EGFR is a transmembrane tyrosine kinase receptor from the HER family which, upon ligand stimulation, activates different signaling pathways involved in tumorogenesis. EGFR can be targeted by monoclonal antibodies, as ...
  • Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    Colomer, Ramon; Aranda-Lopez, Ignacio; Albanell Mestres, Joan; García-Caballero, Tomás; Ciruelos, Eva; Lopez-García, M. A.; Cortés, Javier; Rojo, Federico; Martín, M.; Palacios-Calvo, J. (SpringerOpen, 2018)
    This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish ...
  • Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of spanish medical oncologists
    Sánchez-Rovira, Pedro; Zamora, Pilar; Salvador-Bofill, Javier; Morales, Serafín; Martínez-Jáñez, Noelia; Martínez-de-Dueñas, Eduardo; Lluch, Ana; Illarramendi, José Juan; Gómez-Pardo, Patricia; Gavilá Gregori, Joaquín; García-Palomo, Andrés; García-Mata, Jesús; Fernández, Yolanda; del Barco, Sonia; de Juan, Ana; Ciruelos, Eva; Chacón, José Ignacio; Calvo, Lourdes; Barnadas, Agustí; Albanell Mestres, Joan (Taylor & Francis, 2019)
    Objective: The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently published definition of the optimal sequence for the systemic ...
  • Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
    Calleja, Miguel Angel; Albanell Mestres, Joan; Aranda, Enrique; García-Foncillas, Jesús; Feliu, Anna; Rivera, Fernando; Oyagüez, Itziar; Salinas-Ortega, Laura; Soto Alvarez, Javier (BMJ Publishing Group, 2021)
    Objective: to assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. Methods: a 3-year budget ...
  • Cancer bioMarkers database
    Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-10-17)
    The cancer bioMarkers database is curated and maintained by several clinical and scientific experts in the field of precision oncology supported by the European Union’s Horizon 2020 funding. This database is currently being ...
  • Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
    Tamborero Noguera, David; Rubio Pérez, Carlota, 1990-; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets Trias de Bes, Ignacio; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Torres, Carmen de; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria (BioMed Central, 2018)
    While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a ...
  • Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer
    Guardia Valenzuela, Cristina (Universitat Pompeu Fabra, 2020-01-21)
    El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el pronóstico de esta ...
  • CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer
    Luque, Melani; Cristóbal, Ion; Sanz Álvarez, Marta; Santos, Andrea; Zazo, Sandra; Eroles, Pilar; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; García-Foncillas, Jesús; Rojo, Federico (MDPI, 2022)
    Together with its reported ability to modulate AKT phosphorylation (p-AKT) status in several tumor types, the oncoprotein CIP2A has been described to induce breast cancer progression and drug resistance. However, the ...
  • Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval
    Ciruelos, Eva; Alba, Emilio; López, Rafael; Lluch, Ana; Martín, Miguel; Arroyo, Isabel; Navarro, Beatriz; Carcedo, David; Colomer, Ramon; Albanell Mestres, Joan (Impact Journals, 2019)
    Introduction: Trastuzumab has become the standard treatment for both HER2-positive early and metastatic breast cancer (HER2+ eBC or mBC) since its approval. The objective of the study is to estimate the benefit of adjuvant ...
  • Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
    Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
    Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
    Albanell Mestres, Joan; iMolins, A. B.; Martínez, L. C.; López-Muñiiz, J. I. C.; Gil, E. C.; Juan Ferré, A. de; Barco Berrón, Sonia del; Pérez, Y. F.; Mata, J. G.; Palomo, A. G.; Gregori, J. G.; Pardo, P. G.; Mañas, J. J. I.; Hernández, A. L.; Dueñas-Espín, Iván, 1979-; Jáñez, N. M.; Murillo, S. M.; Bofill, Javier Salvador; Auñón, Pilar Zamora; Sánchez-Rovira, Pedro (Springer, 2017)
    Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. When selecting ...
  • Derived neutrophil-to-lymphocyte ratio predicts pathological complete response to neoadjuvant chemotherapy in breast cancer
    Ocaña, Alberto; Albanell Mestres, Joan; Gianni, Luca (Frontiers, 2022)
    Background: Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative ...
  • Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells
    Oltra Sanchis, Sara; Albanell Mestres, Joan; Moreno-Bueno, Gema (Nature Research, 2023)
    Gasdermin (GSDM)-mediated pyroptosis is functionally involved in multiple diseases, but Gasdermin-B (GSDMB) exhibit cell death-dependent and independent activities in several pathologies including cancer. When the GSDMB ...
  • Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.
    Pavlovic, Milica, 1985-; Arnal-Estapé, Anna ; Rojo, Federico; Bellmunt, Anna ; Tarragona, Maria ; Guiu, Marc; Planet, Evarist; Garcia-Albéniz, Xabier; Morales, Mònica; Urosevic, Jelena ; Gawrzak, Sylwia ; Rovira Guerín, Ana; Prat, Aleix; Nonell Mazelon, Lara, 1972-; Lluch, Ana; Jean-Mairet, Joël ; Coleman, Robert ; Albanell Mestres, Joan; Gomis, Roger R. (Oxford Open , 2015)
    BACKGROUND: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest. METHODS: A de novo unbiased ...
  • Evolución de la DMO durante el tratamiento con inhibidores de aromatasa y su relación con el gen CYP11A1: estudio prospectivo de la cohorte B-ABLE
    Rodríguez Sanz, Maria, 1984-; Prieto-Alhambra, Daniel; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Garrigós, Laia; Albanell Mestres, Joan; Martinez-García, Maria; González, I.; Martos, Tamara; Díez Pérez, Adolfo; Tusquets Trias de Bes, Ignacio; Nogués Solan, Francesc Xavier (Sociedad Española de Investigación Ósea y del Metabolismo Mineral, 2015)
    Objetivos: El objetivo del estudio fue analizar los cambios en la densidad mineral ósea (DMO) a lo largo del tratamiento con inhibidores de aromatasa (IA) en la práctica clínica y evaluar la asociación entre el gen CYP11A1 ...
  • Exploring the association of cancer and depression in electronic health records: combining encoded diagnosis and mining free-text clinical notes
    Leis Machín, Angela 1974-; Casadevall Aguilar, David; Albanell Mestres, Joan; Posso, Margarita; Macià Guilà, Francesc Assís; Castells, Xavier; Ramírez Anguita, Juan Manuel; Martínez Roldán, Jordi; Furlong, Laura I., 1971-; Sanz, Ferran; Ronzano, Francesco; Mayer, Miguel Ángel, 1960- (JMIR Publications, 2022)
    Background: A cancer diagnosis is a source of psychological and emotional stress, which are often maintained for sustained periods of time that may lead to depressive disorders. Depression is one of the most common ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking